臨床外科70巻5号

2015年05月発行

特集 外科医が知っておくべき がん薬物療法の副作用とその対策 症状別対策マニュアル

発熱性好中球減少症—G-CSFはいかなる場合に必要か？

著者： 林直美¹ 森田佐知² 小寺泰弘¹

所属機関： ¹名古屋大学大学院医学系研究科消化器外科学 ²名古屋大学医学部附属病院化学療法部

ページ範囲：P.548 - P.552

【ポイント】
◆すでに発生した発熱性好中球減少症にはリスクに合わせた抗菌薬を投与し，G-CSFの治療的投与は，骨髄機能の回復をみながら行う．
◆G-CSFの予防投与は，化学療法の治療目的，発熱性好中球減少発生リスクに応じて使用を考慮する．

参考文献

1）Caggiano V, Weiss RV, Rickert TS, et al：Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 103：1916-1924, 2005

2）Courtney DM, Aldeen AZ, Gorman SM, et al：Cancer-associated neutropenic fever：clinical outcome and economic costs of emergency department care. Oncologist 12：1019-1026, 2007

3）Elting LS, Lu C, Escalante CP, et al：Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia. J Clin Oncol 26：606-611, 2008

4）Kuderer NM, Dale DC, Crawford J, et al：Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106：2258-2266, 2006

5）Pettengell R, Schwenkglenks M, Leonard R, et al：Neutropenia occurrence and predictors of reduced chemotherapy delivery：results from the INC-EU prospective observational European neutropenia study. Support Care Cancer 16：1299-1309, 2008

6）Klastersky J, Paesmans M, Rubenstein EB, et al：The Multinational Association for Supportive Care in Cancer risk index：A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18：3038-3051, 2000

7）Masaoka T：Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan：executive summary. Clin Infect Dis 39 （Suppl 1）：S49-52, 2004

8）Tamura K：Initial empirical antimicrobial therapy：duration and subsequent modifications. Clin Infect Dis 39 （Suppl 1）：S59-64, 2004

9）Hughes WT, Armstrong D, Bodey GP, et al：2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34：730-751, 2002

10）Smith TJ, Khatcheressian J, Lyman GH, et al：2006 update of recommendations for the use of white blood cell growth factors：an evidence-based clinical practice guideline. J Clin Oncol 24：3187-3205, 2006

11）Crawford J, Ozer H, Stoller R, et al：Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325：164-170, 1991

12）Ajani JA：Optimizing docetaxel chemotherapy in patients with cancer of the gastric and gastroesophageal junction：evolution of the docetaxel, cisplatin, and 5-fluorouracil regimen. Cancer 113：945-955, 2008

13）Aapro MS, Cameron DA, Pettengell R, et al：EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 42：2433-2453, 2006

14）Aapro M, Crawford J, Kamioner D：Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors：where are we now? Support Care Cancer 18：529-541, 2010

15）Earl HM, Hiller L, Dunn JA, et al：NEAT：National Epirubicin Adjuvant Trial—toxicity, delivered dose intensity and quality of life. Br J Cancer 99：1226-1231, 2008

16）Vogel CL, Wojtukiewicz MZ, Carroll RR, et al： First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer：a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 23：1178-1184, 2005